OTCMKTS:PMCUF Pro Medicus (PMCUF) Stock Price, News & Analysis $118.62 0.00 (0.00%) As of 04/24/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Pro Medicus Stock (OTCMKTS:PMCUF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pro Medicus alerts:Sign Up Key Stats Today's Range$118.62▼$118.6250-Day Range$101.50▼$187.0052-Week Range$65.01▼$187.00Volume32 shsAverage Volume1,453 shsMarket CapitalizationN/AP/E Ratio7,908.00Dividend Yield0.02%Price TargetN/AConsensus RatingN/A Company OverviewPro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia.Read More… Pro Medicus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScorePMCUF MarketRank™: Pro Medicus scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pro Medicus. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro Medicus is 7,908.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro Medicus is 7,908.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.14. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverPro Medicus has a short interest ratio ("days to cover") of 640.7, which indicates bearish sentiment.Change versus previous monthShort interest in Pro Medicus has recently decreased by 3.88%, indicating that investor sentiment is improving. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldPro Medicus pays a meaningful dividend of 1.63%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthPro Medicus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Pro Medicus is 133.33%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Pro Medicus' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverPro Medicus has a short interest ratio ("days to cover") of 640.7, which indicates bearish sentiment.Change versus previous monthShort interest in Pro Medicus has recently decreased by 3.88%, indicating that investor sentiment is improving. News and Social Media1.0 / 5News SentimentN/A News SentimentPro Medicus has a news sentiment score of -1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pro Medicus this week, compared to 1 article on an average week.Search Interest1 people have searched for PMCUF on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pro Medicus insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 10.84% of the stock of Pro Medicus is held by institutions.Read more about Pro Medicus' insider trading history. Receive PMCUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCUF Stock News HeadlinesIs Weakness In Pro Medicus Limited (ASX:PME) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?April 21, 2025 | finance.yahoo.comPro Medicus Partners with UCSF for AI Research CollaborationApril 14, 2025 | tipranks.comClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...April 26, 2025 | American Alternative (Ad)BELL POTTER SECURITIES Downgrades Pro Medicus (PMCUF)April 8, 2025 | msn.comPro Medicus Limited Updates on Share Buy-Back ProgramApril 7, 2025 | tipranks.comPro Medicus Limited Announces Cessation of SecuritiesApril 7, 2025 | tipranks.comRBC Capital Sticks to Its Hold Rating for Pro Medicus Limited (PMCUF)April 5, 2025 | markets.businessinsider.comPro Medicus Limited Updates on Market Buy-Back ProgramApril 2, 2025 | tipranks.comSee More Headlines PMCUF Stock Analysis - Frequently Asked Questions How have PMCUF shares performed this year? Pro Medicus' stock was trading at $155.27 at the beginning of the year. Since then, PMCUF stock has decreased by 23.6% and is now trading at $118.62. View the best growth stocks for 2025 here. How do I buy shares of Pro Medicus? Shares of PMCUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolOTCMKTS:PMCUF CIKN/A Webwww.promed.com.au Phone61 3 9429 8800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio7,908.00 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:PMCUF) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro Medicus Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Pro Medicus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.